Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 2/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325090 | 0.83 | ALDH1A1 (0.51) | TDP1TSHRSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL15049917 | 0.81 | ALDH1A1 (0.45) | TDP1TSHRSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6129357 | 0.76 | TDP1 (0.46) | TDP1TSHRSMN1; SMN2GPR35ALDH1A1 | |
| SCHEMBL16225016 | 0.75 | TDP1 (0.58) | TDP1TSHRSMN1; SMN2GPR35ALDH1A1 | |
| SCHEMBL18138439 | 0.74 | TDP1 (0.56) | TDP1TSHRSMN1; SMN2GPR35ALDH1A1 | |
| SCHEMBL3913753 | 0.72 | TSHR (0.51) | TDP1TSHRGPR35ALDH1A1HSD17B10 | |
| SCHEMBL702623 | 0.72 | TDP1 (0.46) | TDP1TSHRSMN1; SMN2GPR35ALDH1A1 | |
| SCHEMBL8911863 | 0.72 | TDP1 (0.54) | TDP1TSHRSMN1; SMN2GPR35ALDH1A1 | |
| SCHEMBL14718636 | 0.71 | MAPT (0.44) | TDP1SMN1; SMN2ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL2027813 | 0.70 | MAPT (0.45) | TDP1TSHRALDH1A1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230092024-A1 | Increasing Efficiency Of Photochemical Reactions On Substrates | CENTRILLION TECHNOLOGIES, INC. | 2023-03-23 | — | — | US | claimed |
| US-20230092024-A1 | Increasing Efficiency Of Photochemical Reactions On Substrates | CENTRILLION TECHNOLOGIES, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2021117680-A1 | BIOLOGICAL SUBSTANCE IMMOBILIZATION MATERIAL | 国立大学法人 東京大学 | 2021-06-17 | — | — | WO | disclosed |
| EP-3802847-A1 | INCREASING EFFICIENCY OF PHOTOCHEMICAL REACTIONS ON SUBSTRATES | Centrillion Technologies, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200397901-A1 | PHOTORESPONSIVE SMOOTHENED LIGAND | THE UNIVERSITY OF TOKYO (JP) | 2020-12-24 | — | — | US | disclosed |
| US-20130165350-A1 | SURFACE LINKERS FOR ARRAY SYNTHESIS | AFFYMETRIX, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130078389-A1 | PATTERN FORMATION METHOD | NIKON CORPORATION (JP) | 2013-03-28 | — | — | US | disclosed |
| EP-1071821-A4 | METHODS FOR REDUCING NON-SPECIFIC BINDING TO A NUCLEIC ACID PROBE ARRAY | AFFYMETRIX INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20010049108-A1 | Methods for reducing non-specific binding to an oligonucleotide array | MCGALL GLENN (US) | 2001-12-06 | — | — | US | disclosed |
| EP-1071821-A1 | METHODS FOR REDUCING NON-SPECIFIC BINDING TO A NUCLEIC ACID PROBE ARRAY | Affymetrix, Inc. (a California Corporation) (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999054509-A1 | METHODS FOR REDUCING NON-SPECIFIC BINDING TO A NUCLEIC ACID PROBE ARRAY | AFFYMETRIX, INC. (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397901-A1 | PHOTORESPONSIVE SMOOTHENED LIGAND | SMO, GLI1, SHH | TDP1 3972/4885TSHR 495/4885SMN1; SMN2 2996/4885 |
| US-20230092024-A1 | Increasing Efficiency Of Photochemical Reactions On Substrates | TYR, PCNA, DNMT1 | TDP1 110/4885TSHR 4716/4885SMN1; SMN2 2286/4885 |
| US-20010049108-A1 | Methods for reducing non-specific binding to an oligonucleotide array | DCLRE1B, CD2BP2, NT5C3B | TDP1 710/4885TSHR 2343/4885SMN1; SMN2 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.